SCC、CYFRA21⁃1及NSE在贝伐珠单抗联合FP治疗肺癌中的临床意义  

The clinical significance of SCC,CYFRA21⁃1 and NSE in the treatment of lung cancer with bevacizumab combined with FP

作　　者：周计 周宗正 潘刚 ZHOU Ji;ZHOU Zongzheng;PAN Gang(The First Department of Oncology,Suixi County Hospital,Huaibei,Anhui,China,235100)

机构地区：[1]濉溪县医院肿瘤一科,安徽淮北235100

出　　处：《分子诊断与治疗杂志》2022年第12期2098-2101,2105,共5页Journal of Molecular Diagnostics and Therapy

基　　金：安徽省科技攻关项目(1604a0802034)。

摘　　要：目的分析(SCC、Cyfra21⁃1)及(NSE)在贝伐珠单联合FP治疗肺癌中的临床意义。方法分析2018年1月至2021年4月濉溪县医院收治肺癌患者83例为研究对象,均给予贝伐珠单抗联合FP化疗方案(FP化疗方案:培美曲塞+卡铂)。评估肺癌患者疗效,对比非缓解组与缓解组临床资料、SCC、CYFRA21⁃1及NSE水平,采用多元Logistic回归分析SCC、CYFRA21⁃1及NSE与肺癌患者疗效;采用COX回归分析影响肺癌患者预后死亡的相关危险因素。结果肺癌患者经贝伐珠单抗+培美曲塞+卡铂治疗,发现CR 18例(21.69%),PR 33例(39.75%),SD 21例(25.30%),PD 11例(13.25%);缓解组例数为51例,非缓解组例数32例。两组年龄、性别、吸烟史、临床分期、组织分化比较差异无统计学意义(P>0.05);两组ECOG评分、SCC、CYFRA21⁃1及NSE比较差异具有统计学意义(P<0.05)。经Logistic回归模型分析得:ECOG评分、SCC、CYFRA21⁃1及NSE与肺癌疗效有关(P<0.05)。预后不良组SCC、CYFRA21⁃1及NSE水平明显高于预后良好组,差异有统计学意义(P<0.05)。ECOG评分、临床分期、SCC、CYFRA21⁃1及NSE是影响肺癌患者预后不良的危险因素(P<0.05)。结论SCC、CYFRA21⁃1及NSE水平低,则说明贝伐珠单联合FP治疗肺癌疗效及预后良好,三因子对肺癌疗效和预后评估均具有重要意义。Objective To analyze the clinical significance of(SCC,CYFRA21⁃1) and(NSE)in bevacizumab combined with FP in the treatment of lung cancer.Methods Retrospective analysis from January 2018 to April 2021,Suixi County hospital treated 83 patients with lung cancer as the research object,who were given bevacizumab combined with FP chemotherapy regimen(FP chemotherapy regimen:pemetrexed+carboplatin).The curative effect of lung cancer patients was evaluated.The clinical data,SCC,CYFRA21⁃1 and NSE levels of the non⁃remission group and remission group were compared.Multivariate Logistic regression was used to analyze the relationship between SCC,CYFRA21⁃1 and NSE and the efficacy of lung cancer patients;COX regression was used to analyze the risk factors affecting the prognosis and death of lung cancer patients.Results In lung cancer patients treated with bevacizumab+pemetrexed+carboplatin,18 cases(21.69%)of CR,33 cases of PR(39.75%),21 cases of SD(25.30%),and 11 cases of PD(13.25%)were found.There were 51 cases in the remission group and 32 cases in the non⁃remission group.There were no differences in age,gender,smoking history,clinical stage and tissue differentiation between the two groups(P>0.05).There were statistical differences in ECOG score,SCC,CYFRA21⁃1 and NSE(P<0.05).Logistic regression model analysis showed that ECOG score,SCC,CYFRA21⁃1 and NSE were related to the curative effect of lung cancer(P<0.05).The levels of SCC,CYFRA21⁃1 and NSE in the poor prognosis group were significantly higher than those in the good prognosis group(P<0.05).ECOG score,clinical stage,SCC,CYFRA21⁃1 and NSE were risk factors for poor prognosis of lung cancer patients(P<0.05).Conclusion The low levels of SCC,CYFRA21⁃1 and NSE indicate that bevacizumab combined with FP has a good curative effect and good prognosis in the treatment of lung cancer,and the three factors are of great significance to the evaluation of the curative effect and prognosis of lung cancer.

关 键 词：SCC CYFRA21⁃1 NSE 贝伐珠单 FP 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]